Literature DB >> 7870923

Stimulant drugs and vigilance performance: a review.

H S Koelega1.   

Abstract

The literature on the effects of some stimulant drugs (amphetamine, methylphenidate, caffeine, and nicotine) on vigilance performance is reviewed. Improvement of overall level of performance (both accuracy and speed) after the intake of amphetamine, caffeine, and nicotine has often been reported, and the decrement in performance with time has been shown to be prevented especially with amphetamine and nicotine. Effects on false alarms are negligible. In studies where a test battery was employed, vigilance tasks appeared to be the most sensitive performance tests in detecting the effects of stimulants; however, different vigilance tasks may measure different aspects of mental functions. There is no support for earlier conclusions that improvements are noticed only in fatigued subjects in protracted sessions. Evidence from several studies does not support the hypothesis that improvements are only a recovery of withdrawal-induced impairment. Because positive effects have been obtained with drugs possessing different mechanisms of action, there is as yet no clear support for a noradrenergic, dopaminergic, or cholinergic theory of sustained attention. Simple neurotransmitter theories of attention and information processing may be untenable.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7870923     DOI: 10.1007/bf02257400

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  48 in total

1.  Mitigation of work decrement.

Authors:  G T HAUTY; R B PAYNE
Journal:  J Exp Psychol       Date:  1955-01

2.  Effects of single and repeated doses of theophylline on aspects of performance, electrophysiology and subjective assessments in healthy human subjects.

Authors:  P Bartel; R Delport; B Lotz; J Ubbink; P Becker
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 3.  Drug therapy. Pharmacologic aspects of cigarette smoking and nicotine addiction.

Authors:  N L Benowitz
Journal:  N Engl J Med       Date:  1988-11-17       Impact factor: 91.245

4.  Processing demands, effort, and individual differences in four different vigilance tasks.

Authors:  H S Koelega; J A Brinkman; L Hendriks; M N Verbaten
Journal:  Hum Factors       Date:  1989-02       Impact factor: 2.888

5.  Effect of coffee on the speed of subject-paced information processing.

Authors:  K Bättig; R Buzzi
Journal:  Neuropsychobiology       Date:  1986       Impact factor: 2.328

6.  Effects of caffeine and cyclizine alone and in combination on human performance, subjective effects and EEG activity.

Authors:  M Clubley; C E Bye; T A Henson; A W Peck; C J Riddington
Journal:  Br J Clin Pharmacol       Date:  1979-02       Impact factor: 4.335

7.  Drugs as research tools in psychology: cholinergic drugs and information processing.

Authors:  D M Warburton; K Wesnes
Journal:  Neuropsychobiology       Date:  1984       Impact factor: 2.328

8.  Effects of nicotine on stimulus sensitivity and response bias in a visual vigilance task.

Authors:  K Wesnes; D M Warburton; B Matz
Journal:  Neuropsychobiology       Date:  1983       Impact factor: 2.328

Review 9.  Benzodiazepines and vigilance performance: a review.

Authors:  H S Koelega
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

10.  The separate and combined effects of scopolamine and nicotine on human information processing.

Authors:  K Wesnes; A Revell
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

View more
  63 in total

1.  Effects of trifluoromethylphenylpiperazine (TFMPP) on interhemispheric communication.

Authors:  HeeSeung Lee; Rob R Kydd; Vanessa K Lim; Ian J Kirk; Bruce R Russell
Journal:  Psychopharmacology (Berl)       Date:  2010-10-06       Impact factor: 4.530

2.  Cholinergic nicotinic systems in Alzheimer's disease: prospects for pharmacological intervention.

Authors:  Robyn Vesey; Jennifer M Birrell; Clare Bolton; Ruth S Chipperfield; Andrew D Blackwell; Tom R Dening; Barbara J Sahakian
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

3.  Riluzole and D-amphetamine interactions in humans.

Authors:  Mehmet Sofuoglu; Andrew J Waters; Marc Mooney; Thomas Kosten
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2007-05-18       Impact factor: 5.067

4.  Performance effects of nicotine during selective attention, divided attention, and simple stimulus detection: an fMRI study.

Authors:  Britta Hahn; Thomas J Ross; Frank A Wolkenberg; Diaa M Shakleya; Marilyn A Huestis; Elliot A Stein
Journal:  Cereb Cortex       Date:  2008-12-10       Impact factor: 5.357

5.  Relative lack of cognitive effects of methylphenidate in elderly male volunteers.

Authors:  Danielle C Turner; Trevor W Robbins; Luke Clark; Adam R Aron; Jonathan Dowson; Barbara J Sahakian
Journal:  Psychopharmacology (Berl)       Date:  2003-05-07       Impact factor: 4.530

Review 6.  Alcohol and vigilance performance: a review.

Authors:  H S Koelega
Journal:  Psychopharmacology (Berl)       Date:  1995-04       Impact factor: 4.530

7.  Amphetamine, cocaine, and dizocilpine enhance performance on a lever-release, conditioned avoidance response task in rats.

Authors:  I M White; J R Christensen; G S Flory; D W Miller; G V Rebec
Journal:  Psychopharmacology (Berl)       Date:  1995-04       Impact factor: 4.530

8.  Effects of nicotinic acetylcholine receptor ligands on behavioral vigilance in rats.

Authors:  J Turchi; L A Holley; M Sarter
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

Review 9.  ADHD and smoking: from genes to brain to behavior.

Authors:  Francis Joseph McClernon; Scott Haden Kollins
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

10.  Modulation of nicotine-induced attentional enhancement in rats by adrenoceptor antagonists.

Authors:  Britta Hahn; Ian P Stolerman
Journal:  Psychopharmacology (Berl)       Date:  2004-07-14       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.